Claire L. Langrish - Discovery Research

基本信息

浏览量：24

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 31 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral Allosteric TYK2 Inhibitor ESK-001 Using a Randomized, Double-Blind, Placebo-Controlled Study Design

Sibel Ucpinar, Joyce K. Kwan, Joshua D. Hoffman, Mera K. Tilley, Jeffrey A. Douglas, Roman G. Rubio, Ruixiao Lu,Philip A. Nunn,Claire L. Langrish

CTS-CLINICAL AND TRANSLATIONAL SCIENCEno. 12 (2024)

引用0浏览0WOS引用

Selective Btk Inhibition by PRN1008/PRN473 Blocks Human CLEC-2, and PRN473 Reduces Venous Thrombosis Formation in Mice

Christopher W. Smith,Joana Campos,Helena C. Brown,Natalie J. Jooss, Vanesa-Sindi Ivanova,Maan Harbi,Lourdes Garcia-Quintanilla,Sian Jossi,Marisol Perez-Toledo, Kieran Rookes,Alexander Brill,Lindsay N. Theodore,Tim Owens,Jacob Lastant, Matthew C. Foulke,Shin Mukai,Michelle Francesco,Michael Storek,Alexandra Hicks,Claire Langrish,Philip A. Nunn,Adam F. Cunningham, Abhi Chauhan,Mark R. Thomas,Steve P. Watson,Phillip L. R. Nicolson

Blood Advances (2024)

引用0浏览0WOS引用

Phase 1 Clinical Trial Evaluating Safety, Exposure and Pharmacodynamics of BTK Inhibitor Tolebrutinib (PRN2246, SAR442168)

Timothy D. Owens,Patrick F. Smith,Andrew Redfern,Yan Xing,Jin Shu,Dane E. Karr,Sonja Hartmann,Michelle R. Francesco,Claire L. Langrish,Philip A. Nunn,Steven G. Gourlay

Clinical and Translational Science（2021）

引用26浏览0WOS引用

Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease

Claire L. Langrish,J. Michael Bradshaw,Michelle R. Francesco,Timothy D. Owens,Yan Xing,Jin Shu,Jacob LaStant,Angelina Bisconte,Catherine Outerbridge,Stephen D. White,Ronald J. Hill,Ken A. Brameld,David M. Goldstein,Philip A. Nunn

JOURNAL OF IMMUNOLOGY（2021）

引用64浏览0WOS引用

Preclinical Mechanisms of Topical PRN473, a Bruton Tyrosine Kinase Inhibitor, in Immune-Mediated Skin Disease Models

Yan Xing,Katherine A Chu, Jyoti Wadhwa, Wei Chen,Jiang Zhu,J Michael Bradshaw,Jin Shu, Matthew C Foulke,Natalie Loewenstein,Philip Nunn,Kolbot By,Pasit Phiasivongsa,David M Goldstein,Claire L Langrish

ImmunoHorizons（2021）

引用13浏览0WOS引用

011 Preclinical Mechanism of Action of PRN1008, a Reversible Covalent Bruton’s Tyrosine Kinase Inhibitor in Clinical Development for Pemphigus

C. L. Langrish, M. R. Francesco,Y. Xing,J. M. Bradshaw,T. D. Owens,P. A. Nunn

Journal of Investigative Dermatology（2019）

引用0浏览0引用

Phase 1 Clinical Trial of PRN2246 (SAR441268), a Covalent BTK Inhibitor Demonstrates Safety, CNS Exposure and Therapeutic Levels of BTK Occupancy

Patrick F. Smith,Timothy D. Owens,Claire L. Langrish,Yan Xing,Michelle R. Francesco,Jin Shu,Sonja Hartmann,Dane Karr,Regan Burns, Rob Quesenberry,Ann Neale, Steve G. Gourlay,Andrew Redfern

MULTIPLE SCLEROSIS JOURNAL（2019）

引用14浏览0引用

Preclinical Mechanism of Action of PRN1008, a Reversible Covalent Bruton’s Tyrosine Kinase Inhibitor in Clinical Development for Pemphigus

Claire Langrish, Kristin MacIntosh

crossref（2019）

引用0浏览0引用

Co‐inhibition of Immunoproteasome Subunits LMP2 and LMP7 is Required to Block Autoimmunity

Michael Basler, Michelle M. Lindstrom,Jacob J. LaStant,J. Michael Bradshaw,Timothy D. Owens,Christian Schmidt,Elmer Maurits,Christopher Tsu,Herman S. Overkleeft,Christopher J. Kirk,Claire L. Langrish,Marcus Groettrup

EMBO Reports（2018）

引用58浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn